5.3.6 Other antiviral drugs

From 3rd July 2020, an interim clinical commissioning policy has been put in place to define routine access to remdesivir in the treatment of COVID-19 across the UK.

  • Concentrate for solution for infusion 5mg/ml vials
  • Powder for concentrate for solution for infusion vials 100mg


  1. Remdesivir is recommended as a treatment option for patients hospitalised with COVID-19 (adults and children aged 12 years and older) in accordance with the criteria set out in the updated policy document (06 November 2020) (see interim clinical commissioning policy for more details). The commissioning policy has been updated to reflect the more positive position on remdesivir supply into the UK. The updated policy includes a clinical pathway and new criteria for initiation of treatment, risk assessment, reassessment and review. Co-administration of dexamethasone and hydrocortisone with remdesivir is included. The maximum treatment course is 5 days in total (comprising a loading dose plus 4 further days of maintenance treatment)
Last updated: 09-11-2020


Home > Formulary > Chapters > 5. Infections > 5.3 Antiviral drugs > 5.3.6 Other antiviral drugs


  • First line
  • Second line
  • Specialist
  • Hospital